PFG Investments LLC cut its holdings in shares of Danaher Co. (NYSE:DHR – Free Report) by 8.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,025 shares of the conglomerate’s stock after selling 471 shares during the quarter. PFG Investments LLC’s holdings in Danaher were worth $1,153,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Decker Retirement Planning Inc. acquired a new position in Danaher during the fourth quarter worth about $31,000. Teachers Insurance & Annuity Association of America purchased a new position in Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher during the third quarter worth about $40,000. FSA Wealth Management LLC purchased a new position in Danaher during the third quarter worth about $50,000. Finally, Darwin Wealth Management LLC purchased a new position in Danaher during the third quarter worth about $55,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Danaher Price Performance
Shares of DHR opened at $247.77 on Wednesday. Danaher Co. has a fifty-two week low of $225.42 and a fifty-two week high of $281.70. The firm’s 50 day moving average price is $235.75 and its 200 day moving average price is $253.65. The company has a market cap of $178.96 billion, a P/E ratio of 47.29, a PEG ratio of 4.43 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.
Danaher Announces Dividend
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on DHR shares. TD Cowen lifted their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. KeyCorp lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group reduced their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Raymond James reduced their target price on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Finally, Guggenheim initiated coverage on shares of Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target on the stock. Six research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $285.81.
View Our Latest Analysis on Danaher
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- ETF Screener: Uses and Step-by-Step Guide
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What is the S&P 500 and How It is Distinct from Other Indexes
- What Does the Future Hold for Eli Lilly?
- The Most Important Warren Buffett Stock for Investors: His Own
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.